Skip to main content
. Author manuscript; available in PMC: 2009 Nov 21.
Published in final edited form as: ACS Chem Biol. 2008 Nov 21;3(11):711–722. doi: 10.1021/cb800120t

Figure 4. Inhibition of DcpS decapping activity by C5-substituted quinazolines.

Figure 4

(A) Radiolabeled m7Gp*pppG was incubated with purified human DcpS (5nM) in the presence of increasing concentrations of C5-quinazolines (D156844 or D156676), a positive control for DcpS inhibition (Cap structure), or a negative vehicle (DMSO) control. The reaction products were separated by thin layer chromatography and visualized with a Phosphorimager. (B) Data for the relative decapping rate vs. concentration of compounds (nM). Structures of the compounds are shown in Table 1. (C) Inhibition of endogenous DcpS decapping activity in 20μg of human K562 erythroleukemia cellular extract with the D156844 or D156676 C5-quinazolines.